Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Find Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Near You

The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective randomized controlled trial evaluates whether a specialized COPD flare-up clinic service improves outcomes in patients following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Patients presenting to the emergency department with AECOPD and discharged or hospitalized will be randomized 1:1 to either structured follow-up in a dedicated flare-up clinic or standard follow-up by scheduled telephone interviews. The researches hypothesize that structured follow-up in a specialized clinic will reduce recurrent exacerbations, optimize long-term COPD management, and improve patients' quality of life compared to standard care.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:

• Prior COPD diagnosis based on clinical and spirometry accepted criteria.

• Acute exacerbation of COPD as the main reason for ED arrival.

• Ability to perform in-person and telephone follow-up.

• Agree to participate, with a signed informed consent.

Locations
Other Locations
Israel
Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906
RECRUITING
Tel Aviv
Time Frame
Start Date: 2026-07-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 240
Treatments
Experimental: Intervention
The intervention will include 3 follow-up visits in the flare up clinic - the first visit (following randomization) will occur one month after hospital discharge (from ED or admission, baseline), the second at 3 months, and the third visit will be at 12 months from baseline. At 6 and 9 months after inclusion there will be an additional phone-call with structured interview similar to that of the control group. Visits include clinical evaluation, symptom assessment, spirometry, oscillometry, inhaler technique review, cardiovascular risk assessment, and treatment optimization according to GOLD recommendations.
No_intervention: Control
The control group will undergo baseline and 12 months in-person assessments including all questionnaires and physiological tests but without any medical interventions. Structured telephone follow-up at 3, 6, and 9 months will be performed by research coordinators to assess for the study outcomes.
Sponsors
Leads: Tel-Aviv Sourasky Medical Center
Collaborators: AstraZeneca

This content was sourced from clinicaltrials.gov